Doximity, Inc. (DOCS) Stock Price, News, Quote & History
This article provides comprehensive financial information for Doximity, Inc. (DOCS), including its current stock price, recent performance, key financial metrics, earnings trends, and analyst insights. It details the company's business overview as a digital platform for medical professionals and allows for comparison with similar companies in the health information services industry.
Does Doximity’s (DOCS) Scale With Physicians and Cash Flow Redefine Its Healthcare Tech Moat?
Doximity (DOCS) has achieved significant market penetration, reaching over 80% of U.S. physicians, and demonstrating strong financial performance with 29.3% annual revenue growth over five years and robust free cash flow. This success has allowed for a US$500,000,000 share repurchase program and investment in AI tools, reinforcing its position in healthcare technology. However, the company's reliance on pharmaceutical marketing spend remains a key risk, and while analysts project substantial revenue and earnings growth, fair value estimates vary significantly.
Price-Driven Insight from (DOCS) for Rule-Based Strategy
This article provides a price-driven analysis for Doximity Inc. Class A (NASDAQ: DOCS), indicating weak sentiment across all time horizons and supporting a short bias. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes elevated downside risk due to a lack of long-term support signals.
Claim your share of the $31M Doximity securities class action settlement
Investors who purchased Doximity common stock between June 24, 2021, and August 8, 2023, may be eligible for a cash payment from a $31 million securities class action settlement. The lawsuit alleged Doximity and its CEO made misleading statements about active users and engagement levels, leading to inflated stock prices. The claim deadline for this settlement is July 16, 2026.
Vanguard reorganizes reporting; affiliates to report DOCS holdings (DOCS)
The Vanguard Group has amended its Schedule 13G/A filing for Doximity Inc. (DOCS), reporting 0 shares beneficially owned due to an internal realignment on January 12, 2026. This change means that certain Vanguard subsidiaries will now report their beneficial ownership separately, as permitted by SEC Release No. 34-39538. The amendment clarifies that this is a reclassification of reporting responsibility rather than a sale of shares, and the subsidiaries will continue to pursue the same investment strategies.
The Bull Case For Doximity (DOCS) Could Change Following Surge In Physician AI Interest And Concerns
A recent Doximity report indicates that 94% of U.S. physicians are either using or interested in AI, which could significantly alter Doximity's investment outlook. While AI is seen as a way to reduce administrative burdens, 71% of physicians are concerned about its accuracy and reliability. Investors should consider Doximity's reliance on pharma marketing and emerging AI competition, alongside its projected revenue growth and fair value, as these factors will shape its future performance.
A Look At Doximity’s Valuation After New Report On Rapid Physician AI Adoption
Doximity is under scrutiny following a report indicating rapid AI adoption among U.S. physicians, contrasting with a significant decline in its share price over the past year. Despite a perceived 47% intrinsic discount and a narrative suggesting a fair value substantially higher than its current trading price due to expected AI-driven growth, concerns linger about monetization challenges and shifts in pharmaceutical marketing spend. The article suggests investors should independently assess these factors to determine Doximity's true investment potential.
Sitaram Siddharth sells Doximity shares worth $58,833
Sitaram Siddharth, Interim PFO and PAO of Doximity Inc. (NASDAQ:DOCS), sold 2,319 Class A Common Stock shares for $58,833 on March 10, 2026, executed via a Rule 10b5-1 plan, while the stock trades near its 52-week low. Simultaneously, Siddharth converted and acquired 5,000 shares each of Class B stock to Class A and through stock option exercises. This transaction follows Doximity's positive fiscal third-quarter results, although analysts offer mixed perspectives on the company's future due to varying market reactions and marketing budget delays.
Doximity (DOCS) interim PFO exercises options, converts B to A, sells stock
Doximity, Inc.'s interim PFO and PAO, Siddharth Sitaram, exercised stock options for 5,000 shares at $4.12 per share and converted Class B shares to Class A. He subsequently sold 2,282 Class A shares at $27.88 each to cover tax withholding, as part of a Rule 10b5-1 trading plan. Following these transactions, Sitaram directly holds 81,451 Class A Common Stock shares.
Doximity (DOCS) interim PFO exercises 5,000 options, sell-to-cover 2,319 shares
Doximity, Inc.'s interim PFO and PAO, Siddharth Sitaram, exercised stock options for 5,000 shares of Class B Common Stock, converting them to Class A Common Stock. He then sold 2,319 Class A shares at $25.37 each in a pre-planned sell-to-cover transaction to satisfy tax withholding obligations. Following these transactions, Sitaram directly holds 84,132 shares of Class A Common Stock.
Doximity interim PFO Sitaram sells $63,622 in shares By Investing.com
Doximity's Interim Principal Financial Officer, Sitaram Siddharth, sold 2,282 shares of Class A Common Stock for $63,622 while also converting Class B shares and exercising stock options. This transaction occurred as the stock trades near its 52-week low, despite InvestingPro analysis suggesting it is undervalued with an impressive gross profit margin. Analysts have offered varied perspectives on Doximity following strong fiscal third-quarter results, with some lowering price targets due to near-term headwinds and others upgrading the stock based on its AI tool suite and perceived overreactions to market concerns.
Doximity interim PFO Sitaram sells $63,622 in shares
Doximity Interim Principal Financial Officer, Sitaram Siddharth, sold 2,282 shares of Class A Common Stock for $63,622 on February 10, 2026, through a Rule 10b5-1 trading plan. This sale occurred while the stock was trading near its 52-week low, despite InvestingPro analysis suggesting it is undervalued. Recent analyst reports show mixed perspectives, with some price target adjustments due to factors like pharmaceutical marketing delays and AI tool assessments.
Sitaram Siddharth sells Doximity shares worth $58,833
Sitaram Siddharth, Interim PFO and PAO of Doximity Inc., sold 2,319 shares of Class A Common Stock for $58,833 on March 10, 2026, as part of a Rule 10b5-1 trading plan. This transaction occurred while Doximity shares were trading near their 52-week low. The company recently reported better-than-expected fiscal third-quarter results, although analyst ratings and price targets show mixed perspectives due to factors like valuation, AI tool suite assessment, and pharmaceutical marketing budget delays.
What Analysts Are Saying About Doximity Stock
Over the past three months, 17 analysts have evaluated Doximity (NYSE: DOCS), presenting a range of outlooks with an average 12-month price target of $44.41, a significant decrease from the previous average of $58.65. While some analysts maintained or raised their ratings, a majority lowered their price targets, despite Doximity showing strong financial performance with high market capitalization, positive revenue growth, and impressive net margins, ROE, and ROA.
Doximity (NYSE: DOCS) director trades options and sells 2,000 shares
A Doximity (NYSE: DOCS) director, Kira Scherer Wampler, executed a stock option for 2,000 shares, converted 2,000 Class B Common Stock shares to Class A, and subsequently sold 2,000 Class A shares at $26.00 per share. These transactions, which occurred on March 3, 2026, were part of a pre-scheduled Rule 10b5-1 trading plan adopted in November 2024. Following these actions, her direct Class A holdings decreased to 19,839 shares.
Assessing Doximity (DOCS) Valuation As Positive Analyst Sentiment Builds Around Its Telehealth Platform
This article analyzes Doximity (DOCS) ahead of its ViVE 2026 conference appearance, focusing on its telehealth platform and digital tools. Despite recent stock weakness, the company is seen as significantly undervalued by analysts, trading at a 43% intrinsic discount and over 50% below target prices. The narrative suggests that AI-powered workflow tools will drive platform usage and revenue growth, making it a potential investment opportunity.
Is Doximity’s (DOCS) ViVE 2026 Pitch a Clue to Its Telehealth Moat?
Doximity (DOCS) recently presented at the ViVE 2026 conference, highlighting its digital healthcare tools and platform capabilities for medical professionals. The article discusses Doximity's investment narrative, including its revenue and earnings forecasts which suggest a significant upside to its current price, while also acknowledging risks such as rising competition and regulatory uncertainty. The company also authorized a US$500 million share repurchase, which may influence near-term per-share metrics.
DOCS SEC Filings - Doximity Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Doximity Inc. (DOCS) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. It details how Doximity reports financial conditions and governance matters, offering analyses of non-GAAP measures and executive transactions. The page also features AI-powered summaries of filings, recent insider trading activities, and key stock data for DOCS.
Doximity CEO ViVE 2026 Talk Puts AI And Pharma Story In Focus
Doximity CEO Jeffrey A. Tangney will speak at the ViVE 2026 conference, highlighting the company's focus on AI-powered workflow tools, pharma relationships, and health system adoption. This event is crucial for investors to gauge Doximity's platform centrality and monetization strategies for AI, especially given its reliance on pharma marketing budgets. Investors should monitor for insights into AI monetization, competition, and leadership consistency with prior messaging.
Doximity’s $31 Million Investor Settlement Clears Initial Hurdle
A federal court has given preliminary approval for Doximity Inc.'s $31 million settlement with investors in a proposed securities class action lawsuit. The lawsuit alleged that Doximity misled investors about its professional social network's metrics, claiming that over 80% of US physicians used its platform. A hearing for final approval is scheduled for June in the US District Court for the Northern District of California.
Doximity Expands AI Tools As Investors Weigh Profit Strength And Growth
Doximity (NYSE: DOCS) is launching new AI tools, including DoxGPT, to enhance its offerings for medical professionals and deepen its role in doctors' workflows. Despite recent share price declines in a challenging digital health sector, the company maintains strong fundamentals and high profit margins. The success of these new AI features in increasing clinician engagement and monetization will be a key factor for investors to watch, especially given competition and reliance on pharmaceutical marketing budgets.
(DOCS) Risk Channels and Responsive Allocation
This article provides an AI-generated analysis of Doximity Inc. Class A (NASDAQ: DOCS), suggesting a near-term neutral sentiment that might pause its mid and long-term weakness. It identifies elevated downside risk due to a lack of long-term support signals and outlines three institutional trading strategies tailored to different risk profiles. The analysis also includes multi-timeframe signal data and emphasizes real-time signal access.
Doximity (DOCS) CEO logs 8,243-share tax-withholding disposition
Doximity, Inc. CEO Jeffrey Tangney reported a tax-related disposition of 8,243 Class A Common Shares on February 15, 2026. These shares were withheld by Doximity to cover tax obligations arising from the vesting of restricted stock units, explicitly noted as a mandated tax-withholding disposition rather than a discretionary market trade. Following this transaction, Tangney directly holds 2,232,810 shares of Doximity Class A Common Stock.
Doximity Inc. (NYSE:DOCS) Fits the "Affordable Growth" Investment Strategy
Doximity Inc. (NYSE:DOCS) is presented as a strong candidate for an "Affordable Growth" investment strategy, characterized by high profitability, robust financial health, and a track record of growth at a reasonable valuation. The company boasts top ChartMill scores for profitability and financial health, with high margins and no debt. While past growth rates have been exceptional, future projections remain positive, and its current valuation is considered fair compared to industry peers and the broader market.
Doximity (DOCS) Is Down 9.8% After New AI Spend, Buyback Plan And Guidance Update – Has The Bull Case Changed?
Doximity (DOCS) reported mixed Q3 2025 results, with increased sales and updated full-year guidance, but a dip in quarterly profit per share due to delayed pharmaceutical budgets and higher AI infrastructure spending. The company authorized a new $500 million share repurchase program. The article explores how this new guidance and AI investment affect Doximity's investment narrative, highlighting the tension between short-term profitability and long-term product investment, and the continued reliance on pharma marketing exposure as both a catalyst and a risk.
(DOCS) Movement as an Input in Quant Signal Sets
This article analyzes Doximity Inc. Class A (NASDAQ: DOCS) through quantitative signals, indicating weak sentiment across all time horizons and supporting a short bias. It outlines institutional trading strategies including long, momentum breakout, and short positions, along with multi-timeframe signal analysis for support and resistance levels. The piece emphasizes elevated downside risk due to a lack of long-term support signals.
Halper Sadeh LLC Encourages Doximity Inc. Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating potential breaches of fiduciary duties by officers and directors of Doximity Inc. (NYSE: DOCS). Long-term shareholders are encouraged to contact the firm to discuss options such as seeking corporate governance reforms or the return of funds to the company. The firm operates on a contingent fee basis, meaning shareholders would not pay out-of-pocket legal fees.
Halper Sadeh LLC Encourages Doximity Inc. Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC is investigating whether officers and directors of Doximity Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders. The firm encourages long-term Doximity shareholders to contact them to discuss potential rights such as seeking corporate governance reforms or the return of funds to the company. Shareholder participation is highlighted as important for improving company practices and enhancing shareholder value.
Halper Sadeh LLC Encourages Doximity Inc. Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Doximity Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders. The firm is encouraging current long-term shareholders to contact them to discuss their legal rights and options, which may include seeking corporate governance reforms or the return of funds to the company. Shareholder involvement is emphasized as a way to improve company policies and enhance shareholder value.
Doximity (DOCS) Q3 Net Margin Near 38% Reinforces Bullish Profitability Narratives
Doximity (DOCS) posted strong Q3 2026 results with revenue of US$185.1 million and a net income of US$61.6 million, leading to a 37.5% net margin. While the company demonstrates high profitability and a solid P/E ratio of 21.4x compared to peers, investors are noting a slowdown in earnings growth from 30.2% to 18.9% year-over-year, with a forecasted 4.9% growth, which shifts focus from rapid expansion to earnings durability. Despite this, the stock appears undervalued with a DCF fair value of US$47.19 against its current price of US$27.73.
Doximity Inc-Class A (NYSE:DOCS) Plummets on Weak Revenue Outlook Despite Q3 Beat
Doximity Inc-Class A (NYSE:DOCS) reported a Q3 beat on revenue and EPS, surpassing analyst expectations. However, the company's shares plummeted in after-hours trading due to a fiscal fourth-quarter revenue outlook that fell short of Wall Street estimates. This guidance miss overshadowed strong user engagement, AI product adoption, and a new $500 million stock repurchase program.
Doximity, Inc.'s (NYSE:DOCS) Popularity With Investors Under Threat As Stock Sinks 27%
Doximity, Inc. (NYSE:DOCS) shares have fallen 27% in the last month, contributing to a 43% drop over the past year. Despite strong recent earnings growth of 44% last year and 82% over three years, its current P/E ratio of 24.8x is high given analyst forecasts for only 1.0% annual growth, significantly less than the market's projected 12%. This disconnect between past performance, future growth estimates, and its elevated P/E ratio suggests potential risks for investors.
Doximity Announces Fiscal 2026 Third Quarter Financial Results
Doximity (NYSE: DOCS) announced its fiscal 2026 third-quarter financial results, reporting total revenues of $185.1 million, a 10% year-over-year increase, and net income of $61.6 million. The company highlights strong user engagement, including over 1 million quarterly active prescribers and significant adoption of its new AI products. Doximity also provided financial guidance for the upcoming fiscal quarter and updated its fiscal year outlook, alongside authorizing a new $500 million stock repurchase program.
Doximity Q3 2026 earnings preview
This article provides a preview of Doximity's Q3 2026 earnings. It is a brief, placeholder article from MSN, indicating that more detailed information would typically follow such an announcement.
Why Doximity (DOCS) Is Down 10.5% After AI Disruption Fears Hit Tech-Health Software Stocks
Doximity's stock has dropped 10.5% due to investor concerns about AI potentially disrupting tech-health software, despite analysts expecting revenue growth and strong customer expansion. While fears of AI disruption and rich valuation are risks, the company's fiscal 2026 revenue guidance, large account expansion, and a significant share buyback program still present a positive investment narrative. Investors are encouraged to consider multiple perspectives on Doximity's valuation and risk profile given the current market sentiment.
monday.com, Braze, Doximity, Freshworks, and BlackLine Shares Plummet, What You Need To Know
Shares of monday.com, Braze, Doximity, Freshworks, and BlackLine experienced significant drops following the release of new AI models from Anthropic and OpenAI. The market reacted to concerns that autonomous AI agents could commoditize traditional software services and render legacy licensing models obsolete, leading to a repricing of the software application industry. monday.com's shares, in particular, have been highly volatile and have declined significantly year-to-date.
Liquidity Mapping Around (DOCS) Price Events
This article analyzes Doximity Inc. Class A (NASDAQ: DOCS) using AI models, indicating weak sentiment across all horizons and supporting a short bias. It provides three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis highlights elevated downside risk for DOCS, with current signals and multi-timeframe support/resistance levels.
Institutional Sentiment Shifts As Doximity Balances Guidance And Growth Story
Institutional investor sentiment regarding Doximity (NYSE:DOCS) is mixed following cautious company guidance and healthcare policy changes, despite a modest increase in hedge fund ownership. The article highlights a debate among investors about whether Doximity is a sentiment-driven healthcare tech stock or a core infrastructure network for U.S. doctors, emphasizing the company's focus on physician engagement, telehealth, and workflow tools. Future performance will depend on addressing guidance, policy clarity, and the uptake of new products.
Should Doximity's Expanding Digital Health Platform Reframe the Core Investment Narrative for DOCS?
Doximity (DOCS) is gaining attention for its expanding digital health offerings, including hiring, telehealth, and workflow tools for clinicians, built on its physician-focused network. Despite mixed analyst sentiment and some concerns about growth expectations and policy uncertainty, its subscription model and leading doctor network are seen as key advantages in the digital healthcare shift. Investors are weighing the company's profitability and evolving market position against its current valuation and future growth prospects.
Why (DOCS) Price Action Is Critical for Tactical Trading
This article analyzes Doximity Inc. Class A (NASDAQ: DOCS) and indicates weak sentiment across all horizons, supporting a short bias. It provides three institutional trading strategies tailored for different risk profiles: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy. The analysis includes multi-timeframe signal analysis with support and resistance levels.
Is It Time To Reconsider Doximity (DOCS) After Recent Share Price Weakness
Doximity (DOCS) has seen recent share price weakness, with a 5.8% decline over the last 7 days. A Discounted Cash Flow (DCF) analysis suggests the stock is 20.7% undervalued at $52.06 per share compared to its current price of $41.26. However, its P/E ratio of 30.70x is above Simply Wall St's proprietary "Fair Ratio" of 21.56x, indicating it might be overvalued on this metric.
Doximity (DOCS) Is Down 13.4% After Cutting 2026 Revenue Outlook Amid Regulatory Pressures - What's Changed
Doximity (DOCS) has seen its shares drop significantly after cutting its fiscal 2026 revenue guidance well below Wall Street expectations. This reduction is attributed to tighter hospital budgets and evolving federal regulations impacting healthcare technology and pharmaceutical advertising. The company's AI tools and core ad business are now under scrutiny as new Medicare reimbursement models and stricter data-sharing policies challenge its potential for operational growth.
Understanding Momentum Shifts in (DOCS)
This article analyzes Doximity Inc. Class A (NASDAQ: DOCS), noting stable neutral readings in shorter time horizons which could signal an easing of a long-term weak bias. It identifies elevated downside risk due to a lack of additional long-term support signals and details three AI-generated institutional trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. The analysis also provides multi-timeframe signal analysis for near-term, mid-term, and long-term perspectives.
Morgan Stanley views Doximity (DOCS) underperformance as attractive entry point amid strong engagement
Morgan Stanley believes the recent underperformance of Doximity (DOCS) presents an attractive entry point for investors. The firm highlights strong engagement metrics as a key factor supporting this view, suggesting that the company's fundamentals remain robust despite its stock performance. Investors are encouraged to consider the current valuation as a potential opportunity.
Avoiding Lag: Real-Time Signals in (DOCS) Movement
This article provides real-time signal analysis and trading strategies for Doximity Inc. Class A (NASDAQ: DOCS), indicating a neutral near-term sentiment and elevated downside risk. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The report also includes a multi-timeframe signal analysis, showing support and resistance levels for various periods.
Doximity Agrees to $31 Million Deal to End Investor Class Action
Doximity Inc. has agreed to pay $31 million to settle an investor class-action lawsuit. The lawsuit claimed the medical professional networking company misled investors about its active user count. The settlement, awaiting preliminary approval, will distribute funds to investors who held Doximity stock between June 2021 and August 2023.
What Doximity (DOCS)'s PeerCheck AI Review Launch and Analyst Support Means For Shareholders
Bank of America recently reiterated a positive rating on Doximity (DOCS) due to growing healthcare provider budgets, increased advertising, and the launch of PeerCheck, an AI review tool. PeerCheck, a physician-led framework for clinical review of medical AI tools, is expected to embed Doximity more deeply into clinicians' workflows. Despite analyst optimism and AI-centric tools, the article highlights risks related to the company's reliance on pharmaceutical marketing spend and regulatory uncertainties.
Technical Reactions to DOCS Trends in Macro Strategies
This article analyzes Doximity Inc. Class A (NASDAQ: DOCS) through technical reactions and macro strategies, highlighting weak near and mid-term sentiment, along with a neutral long-term outlook. It provides specific institutional trading strategies including position trading, momentum breakout, and risk hedging with defined entry zones, targets, and stop losses. The analysis integrates AI-generated signals for multi-timeframe signal strength, support, and resistance levels.
Doximity (DOCS): Assessing Valuation After Analyst Upgrades and Growing AI-Driven Growth Prospects
Following analyst upgrades from Morgan Stanley and Raymond James, Doximity (DOCS) is being re-evaluated for its investment potential, especially given a recent share price pullback and its advancements in AI-driven tools. While the company's valuation narrative suggests it is undervalued with a fair value of $71.11, its current P/E ratio remains higher than a fair ratio and similar to the global healthcare services average. The article emphasizes that this valuation largely depends on successful AI monetization and consistent pharma ad spending.
Doximity director Yang Watkin Phoebe L. sells $217,209 in stock
Yang Watkin Phoebe L., a director at Doximity, recently sold shares of the company's stock totaling $217,209. This transaction represents a notable insider sale that investors may want to monitor.
